Payment overview · 2025
General Payments
$670.54
38 reported records · 16 companies
Healthcare provider profile · identity verified
Reena Enaker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CINCINNATI, OH · NPI 1124388483
Verified facts
What the public records show
CMS Open Payments records show Reena Enaker, M.D. received $670.54 in general payments during 2025 across 38 reported records.
PFIZER INC. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $167.48 | 25.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.15 | 24.9% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.05 | 10.2% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $42.22 | 6.3% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.53 | 4.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.90 | 4.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.96 | 3.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.70 | 2.8% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $17.34 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.27 | 2.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.49 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.90 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.32 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.23 | 2.3% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.54 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.46 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $670.54 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $133.08 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.86 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.38 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.60 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.29 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $45.73 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.40 | 3 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $31.53 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methylprednisolone | Methylprednisolone | 96 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 74 | 33 |
| Lisinopril | Lisinopril | 65 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 61 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 46 | 19 |
| Omeprazole | Omeprazole | 45 | 21 |
| Gabapentin | Gabapentin | 44 | 18 |
| Losartan Potassium | Losartan Potassium | 44 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 17 |
| Azithromycin | Azithromycin | 32 | 31 |
| Fluconazole | Fluconazole | 32 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 16 |
| Nystatin | Nystatin | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | 11 |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Prednisone | Prednisone | 16 | 13 |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | 12 |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Metformin Hcl | Metformin Hcl | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $670.54 · 38 records | PFIZER INC. | CAPLYTA, ELIQUIS, EVENITY, FANAPT, GIVLAARI, Heplisav-B, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, QULIPTA, TRELEGY ELLIPTA, UBRELVY, UNITHROID, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND, ZURZUVAE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error